**Name of journal: World Journal of Diabetes**

**ESPS Manuscript NO: 1679**

**Columns: EDITORIAL**

**Diabetic macular edema: Current management 2013**

Arevalo JF. Diabetic macular edema

J Fernando Arevalo

**J Fernando Arevalo,** Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States

**J Fernando Arevalo,** The Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia

**Author contributions:** Arevalo JF designed and wrote the introductory editorial for the highlight topic: “Diabetic Macular Edema”.

**Correspondence to:** **J Fernando Arevalo, MD, FACS, Chief** of Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Al-Oruba Street, PO Box 7191, Riyadh 11462, Saudi Arabia. arevalojf@jhmi.edu

**Telephone:** +966-1-482-12343860 **Fax:** +966-1-482-1234727

**Received:** December27, 2012 **Revised:** January 23, 2013

**Accepted:** January 29, 2013

**Published online:**

**Abstract**

Diabetic retinopathy (DR) is the leading cause of vision loss of working-age adults,and diabetic macular edema (DME) is the most frequent cause of vision loss related to diabetes. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found the 14-year incidence of DME in type 1 diabetics to be 26%.Similarly the Diabetes Control and Complications Trial reported that 27% of type 1 diabetic patients develop DME within 9 years of onset.The most common type of diabetes, type 2, is strongly associated with obesity and a sedentary lifestyle. An even higher incidence of macular edema has been reported in older patients with type 2 diabetes.Within the last 5 years, the use of intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor (VEGF) agents have come into clinical practice for the management of DME and several recent randomized clinical trials have shown improved effectiveness of ranibizumab compared to focal/grid laser. In this theme issue, we discuss the classification of DR and the treatment options currently available for the treatment of DME including corticosteroids, anti-VEGF agents, combined therapy, enzymatic vitrectomy (vitreolysis), pars plana vitrectomy, and new therapies.

© 2013 Baishideng. All rights reserved.

**Key words:** Diabetic macular edema; Diabetic retinopathy;Diabetic Macular Edema; Enzymatic vitrectomy (vitreolysis); Focal/grid laser; Intravitreal anti-VEGF; Intravitreal corticosteroids; New therapies; Pars plana vitrectomy

Arevalo JF. Diabetic Macular Edema: Current Management 2013.

**Available from:**

**DOI:**

**DIABETIC MACULAR EDEMA**

An estimated 347 million people are affected by diabetes worldwide in 2011, of those 138 million live in [China](http://www.reuters.com/places/china) and India and another 36 million in the United States and Russia. The number of people with diabetes is expected to double by 2030[1].Diabetic retinopathy (DR) is the leading cause of vision loss of working-age adults[[2](http://www.ncbi.nlm.nih.gov/pubmed/9627648)],and diabetic macular edema (DME) is the most frequent cause of vision loss related to diabetes. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found the 14-year incidence of DME in type 1 diabetics to be 26%[[3](http://www.ncbi.nlm.nih.gov/pubmed/9787347)].Similarly the Diabetes Control and Complications Trial (DCCT) reported that 27% of type 1 diabetic patients develop DME within 9 years of onset[[4](http://www.ncbi.nlm.nih.gov/pubmed/7724182)].The most common type of diabetes, type 2, is strongly associated with obesity and a sedentary lifestyle. An even higher incidence of macular edema has been reported in older patients with type 2 diabetes[5].

Argon laser photocoagulation has been the mainstay of treatment for macular edema since the publication of the results of the Early Treatment Diabetic Retinopathy Study (ETDRS), which showed an approximate 50% reduction in the rate of moderate vision loss at 3 years following laser photocoagulation compared to no treatment[[6](http://www.ncbi.nlm.nih.gov/pubmed/2866759)].However, for patients with center involved macular edema, the risk of moderate vision loss at 3 years remained 15% with treatment[[6](http://www.ncbi.nlm.nih.gov/pubmed/2866759)].Since the publication of ETDRS, the DCCT and United Kingdom Prospective Diabetes Study have demonstrated that tight glycemic and blood pressure control decrease the risk of microvascular complications of diabetes, including DR and vision loss[[4](http://www.ncbi.nlm.nih.gov/pubmed/7724182),[7](http://www.ncbi.nlm.nih.gov/pubmed/8366922)–[10](http://www.ncbi.nlm.nih.gov/pubmed/9732337)].As intensive blood pressure and blood sugar control have become the standard of care, visual outcomes have improved, but recent studies from the Diabetic Retinopathy Clinical Research Network indicate that even with the guidelines of tight glycemic and blood pressure control, 12%-13% of patients with foveal centered diabetic macular edema who undergo focal/grid laser lose 10 or more ETDRS letters after 2-3 years of follow-up. Additionally, with a baseline median vision of 20/50-20/63, only 36%-44% of patients gained 10 or more ETDRS letters at 2-3 years of follow-up, indicating the need for improved treatment modalities[[11](http://www.ncbi.nlm.nih.gov/pubmed/19273785)–[13](http://www.ncbi.nlm.nih.gov/pubmed/21459214)].The outcomes may be even worse in developing countries were glycemic and blood pressure are poorly controlled.

Within the last 5 years, the use of intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor (VEGF) agents have come into clinical practice for the management of DME and several recent randomized clinical trials have shown improved effectiveness of ranibizumab compared to focal/grid laser[[12](http://www.ncbi.nlm.nih.gov/pubmed/20427088)–[15](http://www.ncbi.nlm.nih.gov/pubmed/21459215)]. In this theme issue, we discuss the classification of diabetic retinopathy and the treatment options currently available for the treatment of diabetic macular edema including corticosteroids, anti-vascular endothelial growth factor agents, combined therapy, enzymatic vitrectomy (vitreolysis), pars plana vitrectomy, and new therapies.

 Wu *et al* give as the classification of diabetic retinopathy and DME (Manuscript in preparation). It is imperative that retina specialists, general ophthalmologists, internists, and endocrinologists learn to speak the same language in order to provide patients with the best care they deserve. Dhibi and Arevalo review how corticosteroids have emerged as an alternative therapy for persistent DME or refractory to conventional laser photocoagulation and other modalities, due to anti-inflammatory, anti-VEGF and anti-proliferative effects (Manuscript in preparation). Many studies have demonstrated the beneficial therapeutic effect of corticosteroids with improvement to both retinal thickness and visual acuity (VA) in short-term on the treatment of DME. Peribulbar and intravitreal injections have been used to deliver steroids for DME with frequent injections due to the chronic and recurrent nature of the disease. Steroid-related side effects include elevated intraocular pressure, cataract, and injection related complications such as endophthalmitis, vitreous hemorrhage, and retinal detachment particularly with intravitreal steroid injections. In order to reduce the risks, complications, and frequent dosing of intravitreal steroids, intravitreal implants have been developed recently to provide a sustained release of corticosteroids and reduce repeated intravitreal injections for the management of DME. Stefanini *et al* discuss the current status of the use of bevacizumab for the management of DME (Manuscript in preparation). There is a strong evidence supporting that intravitreal bevacizumab injection has a good cost-effective profile in the management of DME and may be associated to laser photocoagulation; however, its clinical superiority regarding the duration of DME regression as well as the improvement of best-corrected VA compared to intravitreal ranibizumab and other intravitreal anti-VEGF therapies are still unclear and deserves further investigation. Krispel *et al* review the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been FDA-approved for the use in the eye, ranibizumab (Manuscript in preparation). Moradi *et al* discuss VEGF Trap-Eye (Aflibercept) for the Management of DME. Aflibercept presents a potential exciting new addition to the armamentarium of current VEGF antagonists available for the treatment of DME and other retinal vascular diseases. However, further studies are indicated to confirm the role, safety, and efficacy of aflibercept for DME (Manuscript in preparation). Ha *et al* explore the current evidence in the literature for the use of vitrectomy in the treatment of DME with and without taut posterior hyaloid or traction (Manuscript in preparation). Based on the published results, further research is needed to prospectively evaluated vitrectomy as a treatment modality for DME with evidence of traction that has been refractory to treatment with other first line agents such as anti-VEGF medications. A larger prospective study is needed not only to assess the validity of benefits of vitrectomy in DME with traction, but also to justify the cost and risks of this invasive procedure. Udaondo *et al* review their experience on enzymatic vitreolysis for diabetic retinopathy and DME. Enzymatic vitreolysiscould be considered a good therapeutic alternative in diabetic retinopathy and macular edema (Manuscript in preparation). Finally, Al Shamsi *et al* review new promising therapies for DME. The treatment of diabetic macular edema is rapidly evolving (Manuscript in preparation). The era of laser therapy is being quickly replaced by an era of pharmacotherapy. Several pharmacotherapies have been recently developed for the treatment of retinal vascular diseases such as diabetic macular edema. Several intravitreal injections or sustained delivery devices have undergone phase 3 testing while others are currently being evaluated. The results of clinical trials have shown the superiority of some of these agents to laser therapy. However, with the availability of several of these newer agents, it may be difficult to individualize treatment options especially those patients respond differently to various therapies. As such, more effort is still needed in order to determine the best treatment regimen for a given patient.

The etiology of DME is multifactorial. Therefore, the study of the important aspects of the pathogenesis and molecular pathways involved in the development of DME has led to the development of improved therapies for DME that have come into use in clinical practice. Additional promising therapeutic agents are currently being evaluated in clinical trials and additional molecular targets are being evaluated. Combined therapies targeting multiple pathways may yield synergistic treatment responses as several cytokines may be involved in the development of DME.

**REFERENCES**

1 World Health Organization Diabetes Fact Sheet Number 312. [cited in 2011]. Available from: http: //www.who.int/mediacentre/factsheets/fs312/en/

2 **Moss SE**, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. *Ophthalmology* 1998; **105**: 998-1003 [PMID: 9627648 DOI: 10.1016/S0161-6420(98)96025-0]

3 **Klein R**, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. *Ophthalmology* 1998; **105**: 1801-1815 [PMID: 9787347 DOI: 10.1016/S0161-6420(98)91020-X]

4 Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. *Ophthalmology* 1995; **102**: 647-661 [PMID: 7724182]

5 **Bhagat N**, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. *Surv Ophthalmol* 2009; **54**: 1-32 [PMID: 19171208 DOI: 10.1016/j.survophthal.2008.10.001]

6 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. *Arch Ophthalmol* 1985; **103**: 1796-1806 [PMID: 2866759 DOI: 10.1001/archopht.1985.01050120030015]

7 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med* 1993; **329**: 977-986 [PMID: 8366922 DOI: 10.1056/NEJM199309303291401]

8 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 854-865 [PMID: 9742977 DOI: 10.1016/S0140-6736(98)07037-8]

9 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853 [PMID: 9742976 DOI: 10.1016/S0140-6736(98)07019-6]

10 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998; **317**: 703-713 [PMID: 9732337 DOI: 10.1136/bmj.317.7160.703]

11 **Beck RW**, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol* 2009; **127**: 245-251 [PMID: 19273785 DOI: 10.1001/archophthalmol.2008.610]

12 **Elman MJ**, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010; **117**: 1064-1077.e35 [PMID: 20427088 DOI: 10.1016/j.ophtha.2010.02.031]

13 **Elman MJ**, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011; **118**: 609-614 [PMID: 21459214 DOI: 10.1016/j.ophtha.2010.12.033]

14 **Mitchell P**, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. *Ophthalmology* 2011; **118**: 615-625 [PMID: 21459215 DOI: 10.1016/j.ophtha.2011.01.031]

15 Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: Three-Year Randomized Trial Results. Ophthalmology. 2012; **119**: 2312-8. [DOI: 10.1016/j.ophtha.2012.08.022]

**P-Reviewers** Koleva-Georgieva DN, Romero-Aroca P, Chung S **S-Editor** Wen LL  **L-Editor**  **E-Editor**